FABP3 and peripheral arterial disease: As of current, our data indicate that an increase in circulating FABP3 may be detrimental to endothelial function, and therefore, therapies aimed at inhibiting FABP3 may improve endothelial function in diseased states, particularly in the cases with chronic elevation of FABP3, such as PAD.